Tony Johnson, Goldfinch Bio CEO (Goldfinch via YouTube)

Kid­ney dis­ease drug­mak­er Goldfinch Bio shuts down

Goldfinch Bio, at­tempt­ing to make treat­ments for kid­ney dis­eases and di­a­bet­ic nephropa­thy, is shut­ting down.

Pres­i­dent and CEO Tony John­son con­firmed to End­points News Fri­day af­ter­noon that the biotech shut down af­ter “fundrais­ing chal­lenges in the cur­rent macro-en­vi­ron­ment.” Fierce Biotech first re­port­ed the news.

John­son, who joined in 2017 af­ter a stint as SVP of ear­ly clin­i­cal de­vel­op­ment at As­traZeneca, said in a text that the com­pa­ny “en­tered the ABC process re­cent­ly,” re­fer­ring to an as­sign­ment for the ben­e­fit of the cred­i­tors, which pro­vides a dif­fer­ent wind-down av­enue than a bank­rupt­cy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.